There are two new highly promising classes of treatments for multiple myeloma. Speaking from the Myeloma 2017 meeting in Edinburgh, UK, Gareth Morgan, MD, FRCP, FRCPath, PhD from the UAMS Myeloma Institute, Little Rock, AR, discusses these exciting developments. Prof. Morgan also highlights the current revolutionary drug classes, which include proteasome inhibitors, monoclonal antibodies and immunomodulatory drugs.
Game-changing drug classes for multiple myeloma
